Side effects of calcium channel blockers

Calcium blockers are associated with a number of side effects, such as edema, allergic reactions, gingival swelling and decreased heartbeat (bradycardia).

Particularly serious side effects include an increase in arteriosclerosis and, as a result, an elevated heart attack risk. Since the early 1990s, that is, for more than 20 years, this alarming fact has been documented by scientific studies.

However, no drug company has yet considered it their responsibility to explore the causes of this issue.

Drugs from the group of calcium channel blockers

Drugs from the group of calcium channel blockers include the following substances:

  • Dihydropyridines (drugs ending with “-dipine“): amlodipine (Norvasc®), nifedipine (Adalat®, Procardia®, Nifediac®), nimodipine (Nimotop®), nitrendipine (Baypress®)
  • Phenylalkylamines: Verapamil (Isoptin®, Tarka®)
  • Benzothiazepines: Diltiazem (Dilatrend®, Dilgamma®, Dilzem®)
  • Antivertiginous agents: Flunarizine (Flunavert®, Natil®, Sibelium®), Cinnarizine (Arlevert®)

Patients find themselves in a vicious circle: As a result of their heart complaints they consult a doctor or cardiologist who prescribes them with calcium blockers. The initial subjective improvement of the patients’ symptoms is passed off as a therapeutic success.

Nobody tells them that the prescribed drugs they receive do not reduce the coronary heart disease, but accelerate it and even increase the heart attack risk in the long run.

Nifedipine is the best known representative from the group of calcium channel blockers.

Fast dissolving dosage forms include warning notices for patients with chronic angina
pectoris, amongst others.

Study identifies cause of side effects and health complications

Until recently, the cause of the serious health complications associated with long-term calcium channel blocker use remained unexplored, implying that side effects were deliberately accepted. Now a study conducted by the Dr. Rath Research Institute sheds some light on this matter.

Published in the American Journal of Cardiovascular Disease in May 2016, the results were made available to medical doctors worldwide.

You can find the study in the world’s largest online medical database: